Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COEP NYSE:CVM NASDAQ:INKT NASDAQ:LPCN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$13.32+5.2%$10.68$2.31▼$14.70$61.03M-0.5945,924 shs41,602 shsCVMCEL-SCI$10.43+12.0%$6.28$1.98▼$39.30$71.78M0.52373,970 shs514,864 shsINKTMiNK Therapeutics$14.24-3.9%$15.41$4.56▼$76.00$67.03M0.33124,068 shs51,696 shsLPCNLipocine$2.91-2.3%$3.14$2.68▼$6.17$16.15M1.2421,049 shs14,860 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics+5.21%-1.04%+21.98%+44.31%+242.24%CVMCEL-SCI+12.03%+9.56%+21.56%+396.67%-67.96%INKTMiNK Therapeutics-3.91%-4.43%-13.91%+104.01%+79.14%LPCNLipocine-2.35%-6.43%-12.61%-13.39%-21.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOEPCoeptis Therapeutics0.657 of 5 stars0.03.00.00.02.71.70.0CVMCEL-SCI0.5262 of 5 stars0.04.00.00.00.01.70.6INKTMiNK Therapeutics2.736 of 5 stars3.35.00.00.01.11.70.6LPCNLipocine2.3847 of 5 stars3.84.00.00.01.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOEPCoeptis Therapeutics 0.00N/AN/AN/ACVMCEL-SCI 0.00N/AN/AN/AINKTMiNK Therapeutics 2.60Moderate Buy$37.50163.34% UpsideLPCNLipocine 3.50Strong Buy$9.00209.28% UpsideCurrent Analyst Ratings BreakdownLatest LPCN, INKT, CVM, and COEP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.008/18/2025INKTMiNK TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$35.00 ➝ $35.008/11/2025LPCNLipocineAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/27/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/10/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOEPCoeptis TherapeuticsN/AN/AN/AN/A$1.47 per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($5.57) per shareN/ALPCNLipocine$11.20M1.41N/AN/A$3.16 per share0.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-201.73%-108.46%N/ACVMCEL-SCI-$26.92M-$9.77N/AN/AN/AN/A-238.05%-104.65%N/AINKTMiNK Therapeutics-$9.51M-$2.88N/AN/AN/AN/AN/A-227.24%11/13/2025 (Estimated)LPCNLipocine$10K-$0.87N/A∞N/AN/A-23.59%-21.91%11/6/2025 (Estimated)Latest LPCN, INKT, CVM, and COEP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025COEPCoeptis TherapeuticsN/A-$1.17N/A-$1.17N/A$0.20 million8/14/2025Q2 2025INKTMiNK Therapeutics-$0.55-$1.06-$0.51-$1.06N/AN/A8/5/2025Q2 2025LPCNLipocine-$0.41-$0.41N/A-$0.41$1.00 million$0.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOEPCoeptis Therapeutics0.020.830.83CVMCEL-SCI0.661.071.09INKTMiNK TherapeuticsN/A0.150.15LPCNLipocineN/A12.7112.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOEPCoeptis Therapeutics13.88%CVMCEL-SCI12.08%INKTMiNK Therapeutics2.87%LPCNLipocine9.11%Insider OwnershipCompanyInsider OwnershipCOEPCoeptis Therapeutics24.25%CVMCEL-SCI9.93%INKTMiNK Therapeutics22.48%LPCNLipocine6.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOEPCoeptis Therapeutics24.82 million3.65 millionNot OptionableCVMCEL-SCI436.88 million64.67 millionOptionableINKTMiNK Therapeutics304.52 million3.51 millionNo DataLPCNLipocine105.42 million5.08 millionNo DataLPCN, INKT, CVM, and COEP HeadlinesRecent News About These CompaniesLipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025August 26, 2025 | prnewswire.comHC Wainwright Issues Negative Outlook for Lipocine EarningsAugust 24, 2025 | americanbankingnews.comLipocine (NASDAQ:LPCN) Given "Buy" Rating at HC WainwrightAugust 22, 2025 | americanbankingnews.comLipocine Announces Financial Results for the Second Quarter Ended June 30, 2025August 5, 2025 | prnewswire.comLipocine doses first patient in phase 3 trial for oral PPD treatmentJune 28, 2025 | uk.investing.comLipocine begins dosing in Phase III postpartum depression trial of LPCN 1154June 27, 2025 | msn.comLipocine Begins Phase 3 Trial for LPCN 1154June 26, 2025 | tipranks.comLipocine Inc.: Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum DepressionJune 26, 2025 | finanznachrichten.deLipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum DepressionJune 26, 2025 | prnewswire.comLipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025June 23, 2025 | prnewswire.comLe partenaire de Lipocine dépose une demande d’approbation au Canada pour un médicament TRT oralJune 9, 2025 | fr.investing.comLipocine annonce le dépôt d'une demande d'autorisation de mise sur le marché pour TLANDO au CanadaJune 9, 2025 | zonebourse.comZLipocine Announces Filing of New Drug Submission for TLANDO® in CanadaJune 9, 2025 | prnewswire.comLe LPCN 1148 de Lipocine mis en avant dans l'édition de juin 2025 de HepatologyMay 23, 2025 | zonebourse.comZLipocine’s LPCN 1148 Gains Fast Track DesignationMay 22, 2025 | tipranks.comLipocine's LPCN 1148 Highlighted in the June 2025 Edition of HepatologyMay 22, 2025 | prnewswire.comLipocine to Present at A.G.P. Healthcare ShowcaseMay 14, 2025 | tipranks.comLipocine to Present at A.G.P.'s Annual Healthcare Company ShowcaseMay 14, 2025 | prnewswire.comLipocine Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2025May 8, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPCN, INKT, CVM, and COEP Company DescriptionsCoeptis Therapeutics NASDAQ:COEP$13.32 +0.66 (+5.21%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$13.34 +0.02 (+0.15%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.CEL-SCI NYSE:CVM$10.43 +1.12 (+12.03%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.46 +0.03 (+0.25%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.MiNK Therapeutics NASDAQ:INKT$14.24 -0.58 (-3.91%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$14.70 +0.46 (+3.23%) As of 08/29/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Lipocine NASDAQ:LPCN$2.91 -0.07 (-2.35%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.97 +0.06 (+2.03%) As of 08/29/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
